| 000 | 01951cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223030317.0 | ||
| 008 | 101106s2010 ua f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aM.Sc | ||
| 099 | _aCai01.19.04.M.Sc.2010.Ah.A | ||
| 100 | 0 | _aAhmed Abdelhamed Elsayed Oda | |
| 245 | 1 | 0 |
_aAnthracycline-based chemotherapy in early breast cancer: Correlation with receptor status (estrogen, progesterone and human epidermal growth factor-2 / _cAhmed Abdelhamed Elsayed Oda ; Supervised Rabab Mohamed Gaafar , Ahmed Abdelmabood Zeeneldin , Amani Mohamed Helal |
| 246 | 1 | 5 | _aالعلاج الكيماوى بالانثراسيكلين فى سرطان الثدى المبكر و علاقته بحالة المستقبلات: الاستروجين و البروجستيرون و الهير 2 نيو |
| 260 |
_aCairo : _bAhmed Abdelhamed Elsayed Oda , _c2010 |
||
| 300 |
_a126 P. ; _c25cm |
||
| 502 | _aThesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Oncology-Medical | ||
| 520 | _aBreast cancer (BC) is a heterogeneous disease that encompasses several distinct entities with different biological characteristics and clinical behavior. The purpose of this study is to correlate between the outcome of early breast cancer patients who received anthracycline-based chemotherapy with the tumor receptor status namely estrogen, progesterone and HER-2 receptor as regard disease free survival and overall survival | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aAnthracyclines | |
| 653 | 4 | _aBreast cancer | |
| 653 | 4 | _aEstrogen receptor | |
| 700 | 0 |
_aAhmed Abdelmabood Zeeneldin , _eSupervisor |
|
| 700 | 0 |
_aAmani Mohamed Helal , _eSupervisor |
|
| 700 | 0 |
_aRabab Mohamed Gaafar , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aSamia _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c32005 _d32005 |
||